IRIS
GALLO, Ciro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.981
NA - Nord America 5.485
AS - Asia 4.259
SA - Sud America 784
AF - Africa 52
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 5
Totale 22.572
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 7.288
US - Stati Uniti d'America 5.431
SG - Singapore 1.589
IE - Irlanda 1.451
CN - Cina 1.046
UA - Ucraina 873
HK - Hong Kong 810
BR - Brasile 678
GB - Regno Unito 624
DE - Germania 594
IT - Italia 361
SE - Svezia 244
FI - Finlandia 235
VN - Vietnam 182
IN - India 166
TR - Turchia 153
GR - Grecia 141
KR - Corea 98
JP - Giappone 73
FR - Francia 50
AR - Argentina 44
AT - Austria 29
EC - Ecuador 25
BD - Bangladesh 22
BE - Belgio 21
CA - Canada 19
ID - Indonesia 18
IQ - Iraq 17
MX - Messico 16
IR - Iran 15
EG - Egitto 12
MA - Marocco 11
ZA - Sudafrica 11
ES - Italia 10
CO - Colombia 9
PL - Polonia 9
CZ - Repubblica Ceca 8
TH - Thailandia 8
TW - Taiwan 8
VE - Venezuela 8
CH - Svizzera 7
CL - Cile 7
NL - Olanda 7
PK - Pakistan 7
UZ - Uzbekistan 7
PH - Filippine 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
EU - Europa 5
JM - Giamaica 5
PY - Paraguay 5
RO - Romania 5
TN - Tunisia 5
PE - Perù 4
SA - Arabia Saudita 4
TT - Trinidad e Tobago 4
AU - Australia 3
DK - Danimarca 3
GH - Ghana 3
HU - Ungheria 3
JO - Giordania 3
KH - Cambogia 3
PT - Portogallo 3
RS - Serbia 3
UY - Uruguay 3
AZ - Azerbaigian 2
BF - Burkina Faso 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
GE - Georgia 2
KE - Kenya 2
KG - Kirghizistan 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PR - Porto Rico 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
HN - Honduras 1
IL - Israele 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
ME - Montenegro 1
ML - Mali 1
MN - Mongolia 1
MT - Malta 1
NI - Nicaragua 1
NP - Nepal 1
PS - Palestinian Territory 1
QA - Qatar 1
Totale 22.570
Salva come PNG Salva come JPEG
Città #
Moscow 2.572
Dublin 1.450
Jacksonville 1.272
Chandler 853
Hong Kong 807
Singapore 540
Santa Clara 535
Princeton 234
Bremen 220
Medford 207
Ashburn 173
Boardman 153
Beijing 142
Bengaluru 142
San Mateo 135
Ann Arbor 124
Wilmington 120
Roxbury 116
Hefei 111
Seoul 95
Woodbridge 85
The Dalles 76
Ho Chi Minh City 64
Dallas 55
São Paulo 54
Caserta 53
Jinan 49
Des Moines 45
Hanoi 41
Mountain View 41
Cambridge 39
Munich 37
Nanjing 36
Los Angeles 33
New York 28
Rio de Janeiro 27
Houston 26
Zhengzhou 23
Vienna 22
Brussels 19
Norwalk 19
Belo Horizonte 17
Düsseldorf 17
Guangzhou 16
Nanchang 16
Napoli 16
Hangzhou 15
Naples 15
Turku 15
Ningbo 14
Nuremberg 14
Changsha 13
Helsinki 13
Curitiba 12
Brasília 11
Campodarsego 11
Scottsdale 11
Seattle 11
Shenyang 11
Tianjin 11
Dearborn 10
Haikou 10
Guarulhos 9
Guayaquil 9
Kunming 9
Padova 9
Quito 9
Salvador 9
Venice 9
Bari 8
Haiphong 8
Juiz de Fora 8
Redwood City 8
Rome 8
Boston 7
Campinas 7
Dhaka 7
Milan 7
Porto Alegre 7
Taiyuan 7
Warsaw 7
Bauru 6
Brno 6
Hebei 6
Istanbul 6
Lanzhou 6
London 6
Ponte San Pietro 6
Stockholm 6
Taizhou 6
Tashkent 6
Tokyo 6
Auburn Hills 5
Baghdad 5
Bologna 5
Bắc Ninh 5
Da Nang 5
Fairfield 5
Goiânia 5
Hải Dương 5
Totale 11.410
Salva come PNG Salva come JPEG
Nome #
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients 315
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 197
Association between thraetened pre-term labour and periodontal disease: does a relationship exist? A matched case-control study 188
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 183
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial 170
Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies 150
Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections 147
Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study 146
Antiproteinuric Response to Dual Blockade of RAS in Primary Glomerulonephritis: Meta-Analysis and Meta-Regression 145
Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials 143
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC 140
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial 139
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study 137
A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan 137
Epidemiological study on behavioural and emotional problems in developmental age: prevalence in a sample of Italian children, based on parent and teacher reports. 136
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials 135
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 133
A prognostic index for patients within the intermediate stage of hepatocellular carcinoma 130
A multivariate strategy for the statistical treatment of chemico-clinical data and the construction of reference regions 130
Adjuvant chemoendocrine therapy for early breast cancer: is it worthwhile? 127
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study) 127
Epidemiology of chronic kidney disease in Italy: the CARHES study 126
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group 126
Clinical and histological aspects of chronic HCV infection and cirrhosis 125
Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer 125
Atti del Convegno della Società Italiana di Statistica Medica ed Epidemiologia Clinica 125
Chronic active hepatitis in Italy: a multicentric study on clinical and laboratory data of 1151 cases. A report from the study group for CAH of the Italiana Association for the Study of the Liver 124
A predictive index of axillary nodal involvement in operable breast cancer 124
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study 124
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme) 123
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial 121
Management of hypertension in chronic kidney disease: the Italian multicenter study. 121
Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patients. 121
Activity and toxicity of gemcitabine and gemcitabine plus vinorelbine in advanced non-small-cell lung cancer elderly patients. Phase II data from the MILES (Multicenter Italian Lung cancer in the Elderly Study) randomized trial 121
[Early assessment of mobility and posture as prognosis indicators] 120
Fattori di rischio per l'infezione tifoidea nell'area geografica del golfo di Napoli 120
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial 120
Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study 119
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer 119
High cardiovascular risk in patients with Type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort Study. 119
Prognostic significance of circulating immune complexes in a long-term follow-up of breast cancer patients 117
Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma. A Cancer of the Liver Italian Program (CLIP 08)retrospective case-control study 115
Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP) 115
Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study 115
Prognosis of CKD Patients Receiving Outpatient Nephrology Care in Italy 115
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study 114
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. 114
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. 113
First-Line Erlotinib Followed by Second-Line Cisplatin- Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial 113
Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy 113
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials 113
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. 112
Application of a statistical approach to determining reference intervals in clinical chemistry 112
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 112
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial 110
Morbidity patterns in aged population in southern Italy. A survey sampling 110
LETTERS TO THE EDITOR: RISK OF WARFARIN DURING PREGNANCY WITH MECHANICAL VALVE PROSTHESES 110
Early PET/CT Scan Is More Effective Than RECIST in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab 110
Differenti modalità di classificazione e significato prognostico delle aritmie ventricolari dopo infarto acuto del miocardio 109
Time spent for activation of non-profit studies in oncology in Italy 109
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials 109
Management of hypertension in chronic kidney disease: the italian multicentric study 108
Informed versus randomised consent to clinical trials 107
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial 106
Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study 106
Efficacia e sicurezza della combinazione colistina-rifampicina in confronto con la colistina in monoterapia nelle infezioni gravi da Acinetobacter baumannii MDR: risultati preliminari 106
Health effects associated with the disposal of solid waste in landfills and incinerators in populations living in surrounding areas: a systematic review 106
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 106
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial 105
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer 105
The role of surgery in transmitting "post-transfusion" hepatitis 105
Consumi, abitudine e atteggiamentei verso alcool, tabacco e caffé. Indagine campionaria in una USL napoletana 105
Il rischio di complicanze nel paziente operato: problemi metodologici 104
c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary limphnode metastases 104
Comparison of predictive accuracy of four prognostic models fr non-metastatic renal cell carcinoma after nephrectomy. A multicentre European study 104
Piccole storie di malati 104
Statistical design in phase II clinical trials and its application in breast cancer 103
Phase I study of carboplatin, cisplatin and cyclophosphamide without and with lenogastrim for the treatment of ovarian cancer 103
Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey 103
Is human hepatocellular carcinoma a hormone-responsive tumor? 103
Risk of warfarin during pregnancy with mechanical valve prostheses 103
Prospective Validation of the CLIP Score: A New Prognostic System for Patients With Cirrhosis and Hepatocellular Carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators 103
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study 103
Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer 102
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study 102
Comparaison de la précision predictive de quatre modèles pronostiques dans le cancer du rein localisé 102
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. 102
Prevalence of varicose veins in an Italian elderly population 101
Dental occlusion and body posture in growing subjects. A population-based study in 12-year- old Italian adolescents 101
Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non-Small-Cell Lung Cancer 100
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. 99
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 99
Tamoxifen in the treatmnent of hepatocellular carcinoma: 5 years results of the CLIP-1 multicentre randomised controlled trial 99
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group 98
Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer 98
Immunosuppressive therapy of HBsAg-positive chronic active hepatitis in childhood: a multicentric restrospective study on 139 patients 98
Hormonal treatment of human hepatocellular carcinoma 98
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system 98
Randomized controlled trial to compare the J and W pouch configurations for ulcerative colitis in the maturation period 97
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials 97
Totale 11.931
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.652
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.652
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021973 0 0 0 0 0 25 236 201 19 256 188 48
2021/20221.310 144 4 3 21 480 5 24 38 46 65 101 379
2022/20233.029 261 53 31 295 432 264 4 177 1.380 17 49 66
2023/20241.039 104 38 101 101 384 30 18 14 3 20 63 163
2024/20252.787 12 28 32 55 408 240 434 274 441 460 211 192
2025/202610.057 383 507 611 635 974 6.947 0 0 0 0 0 0
Totale 22.793